Hangzhou AGS MedTech Co. Ltd. A - Asset Resilience Ratio
Hangzhou AGS MedTech Co. Ltd. A (688581) has an Asset Resilience Ratio of 18.80% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Hangzhou AGS MedTech Co. Ltd. A current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how Hangzhou AGS MedTech Co. Ltd. A's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Hangzhou AGS MedTech Co. Ltd. A total assets.
Liquid Assets Composition Over Time
This chart breaks down Hangzhou AGS MedTech Co. Ltd. A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Hangzhou AGS MedTech Co. Ltd. A balance sheet liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥507.20 Million | 18.8% |
| Total Liquid Assets | CN¥507.20 Million | 18.80% |
Asset Resilience Insights
- Good Liquidity Position: Hangzhou AGS MedTech Co. Ltd. A maintains a healthy 18.80% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Hangzhou AGS MedTech Co. Ltd. A Industry Peers by Asset Resilience Ratio
Compare Hangzhou AGS MedTech Co. Ltd. A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
L&C Bio Co. Ltd
KQ:290650 |
Medical Devices | 2.14% |
|
Cochlear Ltd
AU:COH |
Medical Devices | 9.76% |
|
Shenzhen New Industries Biomedical
SHE:300832 |
Medical Devices | 9.95% |
|
Medacta Group SA
SW:MOVE |
Medical Devices | 0.86% |
|
Sinocare Inc
SHE:300298 |
Medical Devices | 3.53% |
|
COPLAND ROAD CAPITAL NEW
F:A2P |
Medical Devices | 0.00% |
|
Zhejiang Orient Gene Biotech Co Ltd
SHG:688298 |
Medical Devices | 2.82% |
|
Shanghai Kinetic Medical Co
SHE:300326 |
Medical Devices | 28.89% |
Annual Asset Resilience Ratio for Hangzhou AGS MedTech Co. Ltd. A (2021–2025)
The table below shows the annual Asset Resilience Ratio data for Hangzhou AGS MedTech Co. Ltd. A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 22.13% | CN¥592.42 Million ≈ $86.69 Million |
CN¥2.68 Billion ≈ $391.68 Million |
-4.19pp |
| 2024-12-31 | 26.32% | CN¥671.22 Million ≈ $98.22 Million |
CN¥2.55 Billion ≈ $373.11 Million |
+22.79pp |
| 2023-12-31 | 3.54% | CN¥82.42 Million ≈ $12.06 Million |
CN¥2.33 Billion ≈ $341.11 Million |
-8.09pp |
| 2022-12-31 | 11.63% | CN¥55.01 Million ≈ $8.05 Million |
CN¥473.13 Million ≈ $69.23 Million |
+11.31pp |
| 2021-12-31 | 0.32% | CN¥1.09 Million ≈ $159.70K |
CN¥341.99 Million ≈ $50.04 Million |
-- |
About Hangzhou AGS MedTech Co. Ltd. A
Hangzhou AGS MedTech Co., Ltd., together with its subsidiaries, engages in the research, development, production, sale, and service of endoscopic minimally invasive diagnostic and therapeutic instruments in China and internationally. The company offers hemostasis products, including hemoclips and traction clips; biopsy products, such as disposable biopsy, swinging biopsy, and grasping forceps; an… Read more